BRIEF published on 04/29/2026 at 02:30, 4 months 13 days ago Organto Foods annonce des résultats financiers records pour l'exercice 2025. Résultats Financiers Croissance Des Ventes Perte Nette Restructuration De La Dette Aliments Biologiques
BRIEF published on 04/29/2026 at 01:35, 4 months 13 days ago First Helium Inc. Announces Private Placement to Raise C$2 Million Private Placement Insider Participation Regulatory Approvals First Helium Worsley Project
BRIEF published on 04/29/2026 at 01:35, 4 months 13 days ago First Helium Inc. annonce un placement privé pour lever 2 millions de dollars canadiens Placement Privé Approbations Réglementaires Participation Des Initiés Premier Hélium Projet Worsley
BRIEF published on 04/29/2026 at 00:25, 4 months 13 days ago Fountain Asset Corp. Reports 2025 Financial Results Net Asset Value Investment Performance Operating Expenses Financial Results 2025 Fountain Asset Corp.
BRIEF published on 04/29/2026 at 00:25, 4 months 13 days ago Fountain Asset Corp. publie ses résultats financiers pour 2025 Valeur Nette D'actif Performance Des Investissements Résultats Financiers 2025 Frais D'exploitation Fountain Asset Corp.
BRIEF published on 04/29/2026 at 00:05, 4 months 13 days ago LIR Life Sciences Initiates Ex Vivo Study on Protamine's Efficacy in Transdermal Delivery Ex Vivo Study Needle-free Delivery Protamine Enhancement Transdermal Transport Therapeutic Molecules
BRIEF published on 04/29/2026 at 00:05, 4 months 13 days ago LIR Life Sciences lance une étude ex vivo sur l'efficacité de la protamine par voie transdermique. Accouchement Sans Aiguille Amélioration De La Protamine Transport Transdermique Molécules Thérapeutiques Étude Ex Vivo
BRIEF published on 04/29/2026 at 00:05, 4 months 13 days ago Onco-Innovations Successfully Scales Up Key Materials for PNKP Inhibitor Program Drug Development Pharmaceutical Manufacturing Scale-up Onco-Innovations PNKP Inhibitor
BRIEF published on 04/29/2026 at 00:05, 4 months 13 days ago Onco-Innovations réussit à industrialiser la production de matériaux clés pour son programme d'inhibiteurs de PNKP. Développement De Médicaments Fabrication Pharmaceutique Onco-Innovations Inhibiteur De PNKP Mise À L'échelle
BRIEF published on 04/28/2026 at 23:55, 4 months 13 days ago Gabriel Resources Secures $1.5 Million Bridge Loan Amid Financial Strains Gabriel Resources Bridge Loan Financial Strain Proposed Financing ICSID Tribunal
Published on 09/12/2026 at 02:35, 16 hours 33 minutes ago Gamma Resources Announces Extension of Private Placement Closing Date
Published on 09/11/2026 at 23:00, 20 hours 8 minutes ago Rio Grande Resources Engages Machai Capital for Investor Outreach
Published on 09/11/2026 at 22:05, 21 hours 3 minutes ago Usha Resources Announces Leadership Transition
Published on 09/11/2026 at 21:25, 21 hours 43 minutes ago Algo Grande Copper Intersects 30.23 Metres Grading 1.5% CuEq, including 3.55 Metres at 9.4% CuEq and 1.2-Metre Interval at 15.8% CuEq, 100 Metres Vertical Step-Out from Historical Intersects
Published on 09/11/2026 at 17:00, 1 day 2 hours ago Critical Elements Selected for Canada Investment Summit Prospectus, Showcasing Project to Leading Global Investors
Published on 09/12/2026 at 17:50, 1 hour 17 minutes ago New Delhi Marks UN Day for South-South Cooperation with Push to Scale Dryland Innovation Across the Global South
Published on 09/12/2026 at 07:30, 11 hours 37 minutes ago NAGRAVISION Secures Formula 1 Content for RTL Croatia and PRO PLUS Slovenia
Published on 09/11/2026 at 22:15, 20 hours 53 minutes ago Amrize Appoints Mario Gross as President of Building Envelope
Published on 09/11/2026 at 22:10, 20 hours 57 minutes ago Quantinuum to Participate in the Piper Sandler 5th Annual Growth Frontiers Conference
Published on 09/11/2026 at 19:44, 23 hours 23 minutes ago DocMorris announces final conversion price and issue size of its New Convertible Bonds due 2031
Published on 09/11/2026 at 07:00, 1 day 12 hours ago BIOPHYTIS ANNOUNCES COMPLETION OF €5.3 MILLION CAPITAL INCREASE TO FUND ITS PHASE 2 TRIAL IN OBESITY
Published on 09/11/2026 at 07:00, 1 day 12 hours ago BIOPHYTIS ANNONCE LA RÉALISATION D’UNE AUGMENTATION DE CAPITAL DE 5,3 MILLIONS D’EUROS DESTINÉE À FINANCER SON ESSAI DE PHASE 2 DANS L’OBÉSITÉ
Published on 09/10/2026 at 19:30, 1 day 23 hours ago Availability of the 2026 Interim Financial Report
